Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Nestin expression throughout multistep pathogenesis of multiple myeloma

Hana Svachova, Fedor Kryukov, Elena Kryukova, Sabina Sevcikova, Pavel Nemec, Henrieta Greslikova, Lucie Rihova, Lenka Kubiczkova, Roman Hajek

. 2014 ; 164 (5) : 701-709.

Language English Country England, Great Britain

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc14074421

Grant support
NT11154 MZ0 CEP Register
NT12130 MZ0 CEP Register
NT13190 MZ0 CEP Register
NT14575 MZ0 CEP Register

The stem cell marker nestin (NES) is found in dividing cells of developing and regenerating tissues. Upon terminal differentiation, NES expression is diminished but may be re-expressed following injury or in cancer. Surprisingly, we recently confirmed NES as a tumour-specific marker for mature CD138(+) 38(+) plasma cells (PC) in multiple myeloma (MM). The present study analysed NES expression throughout the spectrum of MM developmental stages, starting with individuals with no haematological malignancy, through monoclonal gammopathy of undetermined significance (MGUS) and MM to plasma cell leukaemia (PCL) and MM cell lines. NES was analysed in bone marrow PC of 163 MM, four PCL and nine MGUS patients, 10 individuals with no haematological malignancy and 6 myeloma cell lines (OPM-2, RPMI-8226, MOLP-8, U-266, EJM, NCI-H929) by flow cytometry and/or real-time polymerase chain reaction or immunochemistry. We observed a tendency of increased NES expression in parallel with disease progression. NES was evaluated as a reliable marker for accurate discrimination between MM patients and the control group. High NES levels were strongly associated with the presence of 1q21 gain. For the first time, NES was demonstrated to predict worse response to conventional therapy/novel agents. These results suggest that NES might become a useful clinical parameter with an important role in MM pathogenesis.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc14074421
003      
CZ-PrNML
005      
20200219093124.0
007      
ta
008      
141006s2014 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/bjh.12689 $2 doi
035    __
$a (PubMed)24329895
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Šváchová, Hana $u Babak Myeloma Group, Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic $7 xx0112988
245    10
$a Nestin expression throughout multistep pathogenesis of multiple myeloma / $c Hana Svachova, Fedor Kryukov, Elena Kryukova, Sabina Sevcikova, Pavel Nemec, Henrieta Greslikova, Lucie Rihova, Lenka Kubiczkova, Roman Hajek
520    9_
$a The stem cell marker nestin (NES) is found in dividing cells of developing and regenerating tissues. Upon terminal differentiation, NES expression is diminished but may be re-expressed following injury or in cancer. Surprisingly, we recently confirmed NES as a tumour-specific marker for mature CD138(+) 38(+) plasma cells (PC) in multiple myeloma (MM). The present study analysed NES expression throughout the spectrum of MM developmental stages, starting with individuals with no haematological malignancy, through monoclonal gammopathy of undetermined significance (MGUS) and MM to plasma cell leukaemia (PCL) and MM cell lines. NES was analysed in bone marrow PC of 163 MM, four PCL and nine MGUS patients, 10 individuals with no haematological malignancy and 6 myeloma cell lines (OPM-2, RPMI-8226, MOLP-8, U-266, EJM, NCI-H929) by flow cytometry and/or real-time polymerase chain reaction or immunochemistry. We observed a tendency of increased NES expression in parallel with disease progression. NES was evaluated as a reliable marker for accurate discrimination between MM patients and the control group. High NES levels were strongly associated with the presence of 1q21 gain. For the first time, NES was demonstrated to predict worse response to conventional therapy/novel agents. These results suggest that NES might become a useful clinical parameter with an important role in MM pathogenesis.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a progrese nemoci $7 D018450
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a imunofenotypizace $7 D016130
650    _2
$a plazmocelulární leukemie $x metabolismus $7 D007952
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a monoklonální gamapatie nejasného významu $x metabolismus $7 D008998
650    _2
$a mnohočetný myelom $x diagnóza $x imunologie $x metabolismus $x patologie $7 D009101
650    _2
$a nádorové proteiny $x biosyntéza $x genetika $7 D009363
650    _2
$a staging nádorů $7 D009367
650    _2
$a nestin $x biosyntéza $x genetika $7 D064231
650    _2
$a prognóza $7 D011379
650    _2
$a messenger RNA $x genetika $7 D012333
650    _2
$a RNA nádorová $x genetika $7 D012334
650    _2
$a recidiva $7 D012008
650    _2
$a nádorové buňky kultivované $7 D014407
650    _2
$a nádorové biomarkery $x biosyntéza $x genetika $7 D014408
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Kryukov, Fedor $u Babak Myeloma Group, Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic $7 xx0128646
700    1_
$a Kryukova, Elena $u Babak Myeloma Group, Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic $7 xx0122005
700    1_
$a Ševčíková, Sabina, $d 1972- $u Babak Myeloma Group, Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic $7 mub2015859787
700    1_
$a Němec, Pavel $u Babak Myeloma Group, Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic $7 xx0162732
700    1_
$a Grešliková, Henrieta $u Babak Myeloma Group, Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic; Department of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic $7 xx0122004
700    1_
$a Říhová, Lucie $u Babak Myeloma Group, Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic; Department of Clinical Haematology, University Hospital Brno, Brno, Czech Republic $7 xx0081970
700    1_
$a Bešše, Lenka $u Babak Myeloma Group, Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic $7 mub2014851432
700    1_
$a Hájek, Roman, $u Babak Myeloma Group, Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic; Faculty of Medicine, University of Ostrava and Department of Haematooncology, University Hospital Ostrava, Ostrava, Czech Republic $d 1964- $7 nlk20000083645
773    0_
$w MED00009374 $t British journal of haematology $x 1365-2141 $g Roč. 164, č. 5 (2014), s. 701-709
856    41
$u https://pubmed.ncbi.nlm.nih.gov/24329895 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20141006 $b ABA008
991    __
$a 20200219093526 $b ABA008
999    __
$a ok $b bmc $g 1042304 $s 873333
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2014 $b 164 $c 5 $d 701-709 $i 1365-2141 $m British journal of haematology $n Br J Haematol $x MED00009374
GRA    __
$a NT11154 $p MZ0
GRA    __
$a NT12130 $p MZ0
GRA    __
$a NT13190 $p MZ0
GRA    __
$a NT14575 $p MZ0
LZP    __
$a Pubmed-20141006

Find record

Citation metrics

Archiving options